Cargando…

Immune defects in Alzheimer's disease: new medications development

Alzheimer's disease (AD) is a neurodegenerative disease characterized by the accumulation of intracellular and extracellular aggregates. According to the amyloid beta (Aβ) hypothesis, amyloidosis occurring in the brain is a leading cause of neurodegeneration in AD. Defects in the innate immune...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cashman, John R, Ghirmai, Senait, Abel, Kenneth J, Fiala, Milan
Formato:	Texto
Lenguaje:	English
Publicado:	BioMed Central 2008
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2604897/ https://www.ncbi.nlm.nih.gov/pubmed/19090986 http://dx.doi.org/10.1186/1471-2202-9-S2-S13

Ejemplares similares

Passive immunotherapies targeting Aβ and tau in Alzheimer's disease
por: Plotkin, Steven S., et al.
Publicado: (2020)

Defective mitophagy and the etiopathogenesis of Alzheimer’s disease
por: Zeng, Kuan, et al.
Publicado: (2022)

Reversal of cognitive decline in Alzheimer's disease
por: Bredesen, Dale E., et al.
Publicado: (2016)

Advances in the development of new biomarkers for Alzheimer’s disease
por: Klyucherev, Timofey O., et al.
Publicado: (2022)

Curcumin and Omega-3 Fatty Acids Enhance NK Cell-Induced Apoptosis of Pancreatic Cancer Cells but Curcumin Inhibits Interferon-γ Production: Benefits of Omega-3 with Curcumin against Cancer
por: Fiala, Milan
Publicado: (2015)

New strategies for Alzheimer disease and cognitive impairment
por: Maiese, Kenneth, et al.
Publicado: (2009)

Mitophagy in Alzheimer’s disease: Molecular defects and therapeutic approaches
por: Mary, Arnaud, et al.
Publicado: (2022)

Emerging Developments in Targeting Proteotoxicity in Neurodegenerative Diseases
por: McAlary, Luke, et al.
Publicado: (2019)

New insight into protein glycosylation in the development of Alzheimer’s disease
por: Zhao, Jingwei, et al.
Publicado: (2023)

Triggering Innate Immune Receptors as New Therapies in Alzheimer’s Disease and Multiple Sclerosis
por: Piec, Pierre-Alexandre, et al.
Publicado: (2021)

Anti-amyloid-beta to tau-based immunization: developments in immunotherapy for Alzheimer’s disease
por: Lambracht-Washington, Doris, et al.
Publicado: (2013)

Acquired immunity and Alzheimer's disease
por: Feng, Weixi, et al.
Publicado: (2023)

The immune system on the TRAIL of Alzheimer’s disease
por: Burgaletto, Chiara, et al.
Publicado: (2020)

The Vascular-Immune Hypothesis of Alzheimer’s Disease
por: Mehta, Rashi I., et al.
Publicado: (2023)

Amyloid Beta and Phosphorylated Tau-Induced Defective Autophagy and Mitophagy in Alzheimer’s Disease
por: Reddy, P. Hemachandra, et al.
Publicado: (2019)

Drug development in Alzheimer’s disease: the path to 2025
por: Cummings, Jeffrey, et al.
Publicado: (2016)

Immunotherapy of Mild Cognitive Impairment by ω-3 Supplementation: Why Are Amyloid-β Antibodies and ω-3 Not Working in Clinical Trials?
por: Fiala, Milan, et al.
Publicado: (2018)

Alzheimer's disease risk alleles in TREM2 illuminate innate immunity in Alzheimer's disease
por: Golde, Todd E, et al.
Publicado: (2013)

Medical Biotechnology and Alzheimer’s Disease: New Hopes
por: Akhondzadeh, Shahin
Publicado: (2016)

Distributed Particle Filter for Target Tracking: With Reduced Sensor Communications
por: Ghirmai, Tadesse
Publicado: (2016)

Peripheral immune system in aging and Alzheimer’s disease
por: Cao, Wei, et al.
Publicado: (2018)

Innate Immune and Fungal Model of Alzheimer’s Disease
por: Parady, Bodo
Publicado: (2018)

Innate Immunity and Cell Death in Alzheimer's Disease
por: Lee, SangJoon, et al.
Publicado: (2021)

The aging immune system in Alzheimer’s and Parkinson’s diseases
por: Heavener, Kelsey S., et al.
Publicado: (2022)

The Innate Immune System in Alzheimer's Disease
por: Boutajangout, Allal, et al.
Publicado: (2013)

Microbial involvement in Alzheimer disease development and progression
por: Bulgart, Hannah R., et al.
Publicado: (2020)

Cerebral microinfarct is emergency consequence of Alzheimer's disease: a new insight into development of neurodegenerative diseases
por: Lin, Xinjie, et al.
Publicado: (2022)

Defect and microstructure analysis by diffraction
por: Snyder, Robert L, et al.
Publicado: (1999)

Defective autophagy and Alzheimer’s disease: is calcium the key?
por: Filadi, Riccardo, et al.
Publicado: (2019)

Culprit or Bystander: Defective Mitophagy in Alzheimer’s Disease
por: Xie, Chenglong, et al.
Publicado: (2020)

Defective Autophagy and Mitophagy in Aging and Alzheimer’s Disease
por: Tran, Michael, et al.
Publicado: (2021)

Cerebrovascular insulin receptors are defective in Alzheimer’s disease
por: Leclerc, Manon, et al.
Publicado: (2022)

Exploiting microglial and peripheral immune cell crosstalk to treat Alzheimer’s disease
por: Dionisio-Santos, Dawling A., et al.
Publicado: (2019)

Molecular imaging in Alzheimer's disease: new perspectives on biomarkers for early diagnosis and drug development
por: Nordberg, Agneta
Publicado: (2011)

Recent Developments in New Therapeutic Agents against Alzheimer and Parkinson Diseases: In-Silico Approaches
por: Cruz-Vicente, Pedro, et al.
Publicado: (2021)

The effect of insomnia on development of Alzheimer’s disease
por: Sadeghmousavi, Shaghayegh, et al.
Publicado: (2020)

Rationale for the development of an Alzheimer’s disease vaccine
por: Kwan, Ping, et al.
Publicado: (2019)

The Development of Pharmacological Therapies for Alzheimer’s Disease
por: Lin, Ping, et al.
Publicado: (2021)

Therapeutics of Alzheimer’s Disease: Recent Developments
por: Burns, Scott, et al.
Publicado: (2022)

Druggable monogenic immune defects hidden in diverse medical specialties: Focus on overlap syndromes
por: Boz, Valentina, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_73d98b2cs93oje7vdo5p5l8a68